T2 Biosystems (NASDAQ:TTOO) Now Covered by StockNews.com

Research analysts at StockNews.com began coverage on shares of T2 Biosystems (NASDAQ:TTOO) in a research report issued to clients and investors on Wednesday. The brokerage set a “sell” rating on the medical equipment provider’s stock.

T2 Biosystems Stock Down 6.5 %

Shares of TTOO stock opened at $0.51 on Wednesday. The business’s fifty day moving average price is $1.02 and its 200 day moving average price is $3.15. T2 Biosystems has a 1-year low of $0.42 and a 1-year high of $8.38.

Institutional Investors Weigh In On T2 Biosystems

A hedge fund recently bought a new stake in T2 Biosystems stock. Armistice Capital LLC purchased a new stake in T2 Biosystems, Inc. (NASDAQ:TTOO) in the 2nd quarter, according to its most recent filing with the SEC. The fund purchased 1,658,000 shares of the medical equipment provider’s stock, valued at approximately $8,854,000. Armistice Capital LLC owned about 9.49% of T2 Biosystems as of its most recent filing with the SEC. 23.18% of the stock is currently owned by institutional investors and hedge funds.

About T2 Biosystems

T2 Biosystems, Inc, an in vitro diagnostics company, develops and sells diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine.